Clinical Trial Detail

NCT ID NCT03660826
Title Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer
Recruitment Suspended
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

endometrial adenocarcinoma

uterine corpus serous adenocarcinoma

endometrial carcinoma

Therapies

Olaparib

Cediranib + Olaparib

Age Groups: adult senior

No variant requirements are available.